Business
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures
-Over 90% of patients in the study were opioid free through the end of multimodal treatment with ...
About this update from Vortex Energy Corp.
[{"type":"text","content":"Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n\n -Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX-\n \n\n\n\n -These data have been accepted for oral presentation at the American Academy of Pain Medicine Meeting-\n \n\n\n\n\n\n Vertex Pharmaceuticals Incorporated\n \n (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX\n \n ®\n \n (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. These data showed that the majority of patients (90.9%) in the study were opioid free through the end of treatment (up to 14 days), demonstrating the potential for JOURNAVX as a core element of opioid-free multimodal treatment for moderate-to-severe acute pain after aesthetic and reconstructive procedures. In contrast, the literature shows opioid-free rates of less than 10% with multimodal treatment without JOURNAVX. These data will be presented at the American Academy of Pain Medicine (AAPM) PainConnect 2026 meeting, March 5-8, 2026, in Salt Lake City, UT.\n \n\n This Phase 4 open-label, multicenter, single-arm study evaluated JOURNAVX when administered preoperatively and postoperatively as part of multimodal therapy, most commonly with acetaminophen and ibuprofen, in a range of reconstructive and aesthetic plastic surgeries where patients typically experience moderate-to-severe pain and are typically treated with opioid therapy for at least 72 hours postoperatively. The study dosed 99 patients who underwent aesthetic and reconstructive surgeries, including reconstructive and aesthetic breast surgeries, liposuction or abdominoplasty with liposuction, or turbinoplasties. The primary endpoint was the proportion of patients who achieved excellent, very good or good on the Patient Global Assessment scale at the end of treatment. The study showed that 90.7% of patients (95% CI: 83.1%, 95.7%) rated the effectiveness of JOURNAVX as part of multimodal treatment as excellent, very good or good. 90.9% of patients di...